Review article: Crohn's disease: Monitoring disease activity

Alimentary Pharmacology and Therapeutics, Supplement

Volumn 17, Issue 2, 2003, Pages 11-17

  Sostegni, R ^a   Daperno, M ^a   Scaglione, N ^a   Lavagna, A ^a   Rocca, R ^a   Pera, A ^a  

^a MAURIZIANO HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; CALPROTECTIN;

ANALYTIC METHOD; ANUS FISTULA; CLINICAL PRACTICE; CONFERENCE PAPER; CROHN DISEASE; DISEASE ACTIVITY; DISEASE MARKER; DISEASE SEVERITY; HUMAN; INTERMETHOD COMPARISON; INTESTINE MUCOSA PERMEABILITY; MEDICAL ASSESSMENT; MEDICAL DECISION MAKING; PATIENT MONITORING; PRIORITY JOURNAL; PROGNOSIS; QUALITY OF LIFE; QUESTIONNAIRE; RECURRENT DISEASE; REPRODUCIBILITY; SCORING SYSTEM; VALIDATION PROCESS;

ABDOMINAL PAIN; BIOLOGICAL MARKERS; CROHN DISEASE; ENDOSCOPY, GASTROINTESTINAL; HUMANS; INTESTINAL FISTULA; PROGNOSIS; QUALITY OF LIFE; SEVERITY OF ILLNESS INDEX; SEXUAL DYSFUNCTION, PHYSIOLOGICAL;

EID: 0038574361     PISSN: 09530673     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (35)

1. Sachar DB. Defining clinical activity in Crohn's disease In: Hanauer SB, Jewell DP, Rachmilewitz D, Scholmerich J, eds. Inflammatory Bowel Disease, Dordrecht: Kluwer Academic Publishers, 2002: 32-9.
2. Best WR, Becktel JM, Singleton JW, Kern F Jr. Development of a Crohn's disease activity index. National Cooperative Crohn's Disease Study. Gastroenterology 1976; 70: 439-44.
3. Winship DH, Summers RW, Singleton JW, et al. National Cooperative Crohn's Disease Study: study design and conduct of the study. Gastroenterology 1979; 77: 829-42.
4. de Dombal FT, Softley A. IOIBD report no. 1: Observer variation in calculating indices of severity and activity in Crohn's disease. International Organisation for the Study of Inflammatory Bowel Disease. Gut 1987; 28: 474-81.
5. Harvey RF, Bradshaw JM. A simple index of Crohn's disease activity. Lancet 1980; 1: 514.
6. Myren J, Bouchier IA, Watkinson G, et al. Multinational Inflammatory Bowel Disease Survey 1976-82. A further report on 2,657 cases. Scand J Gastroenterol Suppl 1984; 95: 1-27.
7. Wright JP, Marks IN, Parfitt A. A simple clinical index of Crohn's disease activity - the Cape Town index. S Afr Med J 1985; 68: 502-3.
8. van Hees PA, van Elteren PH, van Lier HJ, van Tongeren JH. An index of inflammatory activity in patients with Crohn's disease. Gut 1980; 21: 279-86.
9. Irvine EJ. Usual therapy improves perianal Crohn's disease as measured by a new disease activity index. McMaster IBD Study Group. J Clin Gastroenterol 1995; 20: 27-32.
10. Present DH, Rutgeerts P, Targan S, et al. Infliximab for the treatment of fistulas in patients with Crohn's disease. N Engl J Med 1999; 340: 1398-405.
11. Drossman DA, Leserman J, Li ZM, Mitchell CM, Zagami EA, Patrick DL. The rating form of IBD patient concerns: a new measure of health status. Psychosom Med 1991; 53: 701-12.
12. Guyatt G, Mitchell A, Irvine EJ, et al. A new measure of health status for clinical trials in inflammatory bowel disease. Gastroenterology 1989; 96: 804-10.
13. Irvine EJ, Feagan B, Rochon J, et al. Quality of life: a valid and reliable measure of therapeutic efficacy in the treatment of inflammatory bowel disease. Canadian Crohn's Relapse Prevention Trial Study Group. Gastroenterology 1994; 106: 287-96.
14. Brignola C, Campieri M, Bazzocchi G, Farruggia P, Tragnone A, Lanfranchi GA. A laboratory index for predicting relapse in asymptomatic patients with Crohn's disease. Gastroenterology 1986; 91(6): 1490-4.
15. Boirivant M, Leoni M, Taricotti D, Fais S, Squarcia O, Pallone F. The clinical significance of serum C reactive protein levels in Crohn's disease. J Clin Gastroenterol 1988; 10: 401-5.
16. Tibble JA, Sigthorsson G, Bridger S, Fagerhol MK, Bjarnason I. Surrogate markers of intestinal inflammation are predictive of relapse in patients with inflammatory bowel disease. Gastroenterology 2000; 119(1): 15-22.
17. Suenaert P, Bulteel V, Lemmens L, et al. Anti-tumor necrosis factor treatment restores the gut barrier in Crohn's disease. Am J Gastroentrol 2002; 97(8): 1867-8.
18. Sturniolo GC, Di Leo V, Ferronato A, D'Odorico A, D'Inca R. Zinc supplementation tightens 'leaky gut' in Crohn's disease. Inflamm Bowel Dis 2001; 7(2): 94-8.
19. Arnott IDR, Drummond H, Gosh S. Gut mucosal secretion of interleukin 1β and interleukin-8 predicts relapse in clinically inactive Crohn's disease. Dig Dis Sci 2001; 46: 402-9.
20. D'Inca R, Di Leo V, Corrao G, et al. Intestinal permeability test as a predictor of clinical course in Crohn's disease. Am J Gastroenterol 1999; 94(10): 2956-60.
21. Waye JD. The role of colonoscopy in the differential diagnosis of inflammatory bowel disease. Gastrointest Endosc 1977; 23(3): 150-4.
22. Modigliani R, Mary JY presenting the GETAID. Reproducibility of colonoscopic findings in Crohn's disease: a prospective multicenter study of interobserver variation. Groupe d'Etudes Therapeutiques des Affections Inflammatoires du Tube Digestif (GETAID). Dig Dis Sci 1987; 32(12): 1370-9.
23. Mary JY, Modigliani R. Development and validation of an endoscopic index of the severity for Crohn's disease: a prospective multicentre study. Groupe d'Etudes Therapeutiques des Affections Inflammatoires du Tube Digestif (GETAID). Gut 1989; 30(7): 983-9.
24. Modigliani R, Mary JY, Simon JF, et al. Clinical, biological, and endoscopic picture of attacks of Crohn's disease. Evolution on prednisolone. Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives. Gastroenterology 1990; 98(4): 811-8.
25. Landi B, Anh TN, Cortot A, et al. Endoscopic monitoring of Crohn's disease treatment: a prospective, randomized clinical trial. The Groupe d'Etudes Therapeutiques des Affections Inflammatoires Digestives. Gastroenterology 1992; 102(5): 1647-53.
26. Cellier C, Sahmoud T, Froguel E, et al. Correlations between clinical activity, endoscopic severity, and biological parameters in colonic or ileocolonic Crohn's disease. A prospective multicentre study of 121 cases. The Groupe d'Etudes Therapeutiques des Affections Inflammatoires Digestives. Gut 1994; 35(2): 231-5.
27. D'Haens G, Van Deventer S, Van Hogezand R, et al. Endoscopic and histological healing with infliximab anti-tumor necrosis factor antibodies in Crohn's disease: a European multicenter trial. Gastroenterology 1999; 116(5): 1029-34.
28. Olaison G, Sjodahl R, Tagesson C. Glucocorticoid treatment in ileal Crohn's disease: relief of symptoms but not of endoscopically viewed inflammation. Gut 1990; 31(3): 325-8.
29. D'Haens G, Geboes K, Ponette E, Penninckx F, Rutgeerts P. Healing of severe recurrent ileitis with azathioprine therapy in patients with Crohn's disease. Gastroenterology 1997; 112(5): 1475-81.
30. D'Haens G, Geboes K, Rutgeerts P. Endoscopic and histologic healing of Crohn's (ileo-) colitis with azathioprine. Gastrointest Endosc 1999; 50(5): 667-71.
31. Colombel JF, Rutgeerts P, Yan S, et al. Infliximab maintenance treatment results in lower hospitalization rate in Crohn's disease patients. Gastroenterology 2002; 122: A613(Abstract).
32. D'Haens G, Noman M, Baert F, et al. Endoscopic healing after infliximab treatment for Crohn's disease provides a longer time to relapse. Gastroenterology 2002; 122: A100 (Abstract).
33. Daperno M, Van Assche G, Bulois P, et al. Development of Crohn's disease endoscopic score (CDES): a simple index to assess endoscopic severity of Crohn's disease. Gastroenterology 2002; 122: A216(Abstract).
34. Rutgeerts P, Geboes K, Vantrappen G, et al. Natural history of recurrent Crohn's disease at the ileocolonic anastomosis after curative surgery. Gut 1984; 25: 665-72.
35. Rutgeerts P, Geboes K, Vantrappen G, Beyls J, Koremans R, Hide M. Predictability of the postoperative course of Crohn's disease. Gastroenterology 1990; 99(4): 956-63.